Affiliation:
1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2. M.V. Lomonosov Moscow State University
3. Immunology Institute, Federal Medical and Biological Agency of Russia
Abstract
Background. Chaperone proteins nucleolin (NCL, or C23) and nucleophosmin (NPM, or B23) regulate key cell functions. The most tumors are characterized by over-expression of these proteins, especially in cell nuclei and on the сell surface, as NCL. Differential expression of NCL/NPM in tumor and normal cells is the basis of selective cytotoxicity of cationic peptides – expected ligands for these proteins. Objective. Analysis of the interactions between nucleolin and some peptides with high nonspecific toxicity for tumor cells. Materials and methods. The interaction of 4 previously characterized cationic peptides with nucleolin dimer was analyzed by pair molecular docking using Maestro 11 program. Results and conclusion. It is shown that these peptides can associate with receptor nucleolin molecules, forming energy-stable complexes. In the active centre of NCL molecule were found, at least, 7 positions of amino acids, which bind to the tested peptides at a high frequency (43–100 %). This indicates the conservative structure of dimer NCL, its stable binding to peptide ligands and the possibility of design the optimal structure of cationic peptides that induce tumor cell death due to competing binding to the target proteins.
Publisher
Publishing House ABV Press
Subject
Cancer Research,Biochemistry (medical),Genetics (clinical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference12 articles.
1. Fujiki H., Watanabe T., Suganuma M. Cell-sufase nucleolin acts as a central mediator for carcinogenic, anti-carcinogenic, and disease-related ligands. J Cancer Res Clin Oncol 2014;140(7):689–99. DOI: 10.1007/s00432-014-1587-5. PMID: 24469254.
2. Koutsioumpa M., Papadimitriou E. Cellsuface nucleolin as a target for anti-cancer therapies. Recent Part Anticancer Drug Discov 2018;9(2):137–52. PMID: 24251811.
3. Lushnikova A., Ponkratova D., Andreev S. et al. A rossibility for therapy of metastatic cutaneous melanoma with cationic peptides. Eur J Cancer 2017;72(Sl): 127–28.
4. Lushnikova A.A., Ponkratova D.A., Rudakova A.A. et al. The mechanisms of antitumor toxicity in a number of cationic peptides. Modern Science 2017;11:124–6.
5. Lushnikova A.A., Ponkratova D.A., Morozova L.F., Andreev S.M. Induction of apoptosis in cutaneous melanoma cells by cationic peptides. Int Sci J 2017;7– 2(61):75–9.